Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics
NCT ID: NCT01944189
Last Updated: 2014-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
70 participants
INTERVENTIONAL
2013-09-30
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is as a strategy towards improved recommendations in resource limited countries during artemether -lumefantrine (AL) treatment in order to maximize the public health benefits.
This is observational population pharmacokinetics study with a nested comparative bioavailability study.The study is intended to describe the variability in lumefantrine blood levels among under five year old Ugandan children with uncomplicated falciparum malaria receiving current standard artemether-lumefantrine dose regimens. Findings will form a basis for development of rational dosage recommendations. The nested comparative bioavailability study will explore effect of profiled local food intake (maize porridge plus vegetable oil versus milk) on lumefantrine uptake. As a strategy towards improved recommendations in resource limited countries during AL treatment in order to maximize the public health benefits. As a secondary objective we will correlate the variability in lumefantrine uptake to malaria treatment outcome and safety profile in this population.
Research hypotheses
1. The population pharmacokinetic profile of lumefantrine among under five year old children in Uganda with uncomplicated falciparum malaria is not affected by demographic factors.
2. There is no difference in the bioavailability of lumefantrine when artemether-lumefantrine is received with maize porridge plus vegetable oil versus milk among under five year old Ugandan children treated for uncomplicated falciparum malaria.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children
NCT00540202
Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.
NCT02089841
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
NCT00529867
Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg
NCT01619878
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia
NCT06300970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Artemether-lumefantrine is currently the first line treatment of uncomplicated malaria in Uganda and several countries in sub Saharan Africa. Currently the recommended dose regimens for children, the most vulnerable population are still empirically weight based derivations based on mainly clinical experience from studies done among adults. Yet children are physiologically different from adults. In particular lumefantrine, a long acting agent ensuring radical cure is highly lipophilic, and has variable oral bioavailability. High variability of lumefantrine uptake and its long half life render it liable to selection pressure if sub-therapeutic concentrations prevail for long periods. Recommended milk or high fat diet to improve its bioavailability may not be available in resource limited settings. In Mwebaza et al ., 2013, our health volunteer crossover bioavailability study preceding the planned patients study, lumefantrine exposure was comparable in milk and maize porridge plus oil study groups. Whereas both fasted and maize porridge groups demonstrated similarly much lower ranges of lumefantrine exposures relative to milk. The greatly improved absorption is attributed to the little fat used to fortify maize porridge. We believe that findings in healthy adult volunteers are relevant for vulnerable African children treated with AL for P. falciparum malaria but this needs to be confirmed.
Objectives
1. To describe the population pharmacokinetics of lumefantrine among under five year old children in Uganda receiving AL for uncomplicated falciparum malaria (Main study).
The described PPK profile will be correlated to treatment outcomes and will form a basis for dose recommendations.
2. To compare the effects of maize porridge plus vegetable oil versus milk on the bioavailability of lumefantrine among under five year old Ugandan children receiving artemether- lumefantrine for uncomplicated falciparum malaria (Nested Study).
This study will establish whether it is possible to recommend fortification of carbohydrate rich food with little fat (maize porridge plus vegetable oil) to achieve similarly optimal absorption of lumefantrine , if milk is not available in resource limited setting during artemether lumefantrine treatment for uncomplicated malaria.
Mani sub-study (1). A single centre open-label prospective non-comparative pharmacokinetic study will be carried out at the Department of Pharmacology \& Therapeutics, Makerere University College of Health Sciences, at Mulago Hospital Complex, Kampala, Uganda. Study will include children (less than 5 years, n=70) diagnosed with uncomplicated falciparum malaria destined to receive standard fixed-weight-based six-dose regimen of artemether-lumefantrine for 3 days on outpatient basis . A full population pharmacokinetic design will be employed to obtain sparse venous plasma samples from participants at scheduled periods during a 28 day follow up period. Each participant will provide between 1 to 8 samples during the 28 day follow up period. Venous plasma levels of lumefantrine (L) and its metabolite desbutyl-lumefantrine (DL) will be determined using liquid chromatography and mass spectrometry tandem (LCMS/MS) at the Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Outcome variables will be pharmacokinetic (PK) exposure parameters of L and DL. Sparse PK data will be pooled for evaluation of both individual and population PK parameter estimates of lumefantrine using NONMEM. Impact of patients' explanatory variables on PK parameters will be assessed. Secondary outcomes will include be adverse events and day 28 treatment outcome.
Nested sub-study (2), is a comparative bioavailability study to compare lumefantrine bioavailability after the first oral dose of AL among pediatric patients receiving standard care. Forty eight out of the 70 under five year old children with uncomplicated malaria will be randomized to receive AL with either milk (n=24) or local maize porridge plus oil (n=24). Venous plasma concentrations (1 ml, whole blood) will be obtained up to 8 hours (at 0, 1, 1.5, 2, 3, 4, 6, 8) after the first using an intensive pharmacokinetic sampling design. Thereafter 1 to 8 sparse venous blood samples will be obtained during a 28 day follow up period to contribute to the PPK study pool. Primary Pharmacokinetic endpoints and outcomes will be exposure parameters after first dose, up to 8 h. Peak concentrations (Cmax) and early exposure (AUC0-8h) will be used for relative bioavailability evaluations using confidence interval approach for average bioequivalence. Secondary end points will be day 28 in follow up with lumefantrine PK exposure (AUC0-28d and AUC0-∞) and day 28 treatment outcomes as secondary outcomes. Correlation of overall exposure (AUC0-28d and AUC0-∞) to clinical and parasitological response to AL treatment will be explored.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Food Supplement
Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.
A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm
Food
Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)
Food arms:
Standard arm = Milk
Experimental arm = maize porridge plus oil
Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)
Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)
Food Supplement Arm
Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.
A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm
Food
Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)
Food arms:
Standard arm = Milk
Experimental arm = maize porridge plus oil
Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)
Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Food
Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)
Food arms:
Standard arm = Milk
Experimental arm = maize porridge plus oil
Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)
Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 6 months to ≤5 years.
* For nested comparative bioavailability study, age \>1 to ≤5 years of age, to avoid intense blood draws from younger children
* Weight ≥5 kg.
* For nested comparative bioavailability study, restrict evaluation to 2 weight/dose groups \>5 to \< 15kg and 15 to \< 25kg
* Within 10 km radius from recruitment site
* Informed consent from parent or guardian
* Willingness to adherence to study procedures
Exclusion Criteria
* Mixed plasmodial infection
* Hemoglobin \< 5 mg/dl
* Weight \< 5kg
* Allergy to study medication or milk
* Medication which known to inhibit or induce CYP3A4/5 examples ketoconazole, erythromycin, steroids, antidepressants, anticonvulsants, antiretroviral drugs.
* Receipt of artemisinin containing compounds in the past 7 days or lumefantrine in the past 28 days
6 Months
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Swedish International Development Cooperation Agency (SIDA)
OTHER_GOV
Makerere University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
College of Health Sciences
Dr Norah Mwebaza
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Norah Mwebaza, MBChB M Sc
Role: PRINCIPAL_INVESTIGATOR
• Department of Pharmacology and Therapeutics, Makerere University College of Health Sciences (MakCHS), Uganda
Urban Hellgren, MD PhD
Role: STUDY_CHAIR
Div Infectious Diseases, Karolinska Institutet (KI) , Sweden
Lars L Gustaffson, MD PhD
Role: STUDY_CHAIR
Dep Lab Medicine, Div Clinical Pharmacology, KI
Paul Waako, PhD
Role: STUDY_CHAIR
Department of Pharmacology and Therapeutics, MakCHS, Kampala, Uganda
Celestino Obua, PhD
Role: STUDY_CHAIR
Department of Pharmacology and Therapeutics, MakCHS, Kampala, Uganda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pharmacology & Therapeutics, MakCHS, Mulago Hospital Complex
Kampala, , Uganda
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Mwebaza N, Jerling M, Gustafsson LL, Obua C, Waako P, Mahindi M, Ntale M, Beck O, Hellgren U. Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):66-72. doi: 10.1111/bcpt.12065. Epub 2013 Apr 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009/054
Identifier Type: OTHER
Identifier Source: secondary_id
HS 567
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.